Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECT Imaging Targeting GPC3 in HCC
NCT07353333Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Aug 2026
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Open-label, single-arm trial of iodine-131-aGPC3-Scfv in hepatocellular carcinoma (HCC). Primary endpoint: Radiation dose to human body at 1 year. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
iodine-131-aGPC3-Scfv
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07353333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353333.